Guide to NRTI Based HIV Treatment and Medication Selection

Nucleoside reverse transcriptase inhibitors, commonly called NRTIs, are an important component of many HIV treatment regimens. These medicines interfere with HIV reverse transcriptase, an enzyme the virus needs to make copies of itself. NRTIs are generally used in combination with another active antiretroviral medicine.

Antiretroviral therapy has changed substantially over time, and NRTIs remain important components of many combination regimens. NRTIs work by interfering with reverse transcriptase, which HIV uses to convert its genetic material into a form that can support viral replication. Current guidance generally uses an NRTI backbone together with another active antiretroviral drug, although some treatment approaches can limit or avoid NRTI use in specific circumstances.

Understanding NRTI Based HIV Treatment

NRTIs are medicines that resemble naturally occurring building blocks used during genetic replication. After activation inside cells, they can interfere with HIV DNA synthesis. Because HIV can develop resistance when treatment is incomplete or ineffective, combination therapy is used to provide sustained suppression of viral replication.

Common considerations when NRTI containing therapy is selected include:

• Tenofovir disoproxil fumarate and tenofovir alafenamide are commonly used forms of tenofovir.
• Lamivudine and emtricitabine are frequently used as NRTI partners.
• Abacavir can be used in selected treatment situations after appropriate clinical assessment.
• Some older NRTIs are no longer commonly used because of safety concerns or the availability of newer options.
• Fixed dose combinations can combine two NRTIs into one tablet, but an NRTI combination tablet may not by itself constitute a complete HIV treatment regimen.

The World Health Organization currently identifies dolutegravir based treatment with an NRTI backbone as the preferred initial approach for many people starting HIV treatment. The exact regimen, however, depends on individual clinical circumstances and applicable treatment guidelines.

Factors That Influence Medication Selection

Choosing an NRTI based regimen involves more than selecting medicines from the same drug class. Healthcare professionals consider laboratory results, previous treatment history, possible resistance, other medications, and conditions that can affect drug safety or effectiveness.

Important factors can include:

• Kidney function: Some tenofovir formulations require particular attention to renal function and dosing.
• Hepatitis B infection: Tenofovir combined with lamivudine or emtricitabine can have activity against both HIV and hepatitis B, making hepatitis B status relevant when selecting therapy.
• Previous treatment: Earlier antiretroviral exposure and documented resistance can influence which medicines remain appropriate.
• Drug interactions: Other prescription medicines, over the counter medicines, and supplements may affect treatment choices.
• Pregnancy and reproductive considerations: Treatment selection may require consideration of pregnancy status and current recommendations.
• Tolerability and safety: Potential adverse effects and existing medical conditions are considered when comparing available options.

Current HIV guidelines also emphasize that treatment should be individualized rather than selected solely according to the NRTI class.

Monitoring During NRTI Containing Therapy

After treatment begins, ongoing medical monitoring helps determine whether the regimen is controlling HIV and remains appropriate. Viral load testing is particularly important for assessing response to antiretroviral therapy. Healthcare professionals may also monitor kidney or liver function and other laboratory measures depending on the medicines being used.

Regular follow up can help identify:

• Changes in HIV viral load
• Changes in CD4 cell count when clinically appropriate
• Possible medication related adverse effects
• Kidney or liver function changes
• Potential drug interactions
• Treatment adherence challenges
• Evidence suggesting treatment failure or resistance

WHO guidance also emphasizes maintaining access to antiretroviral treatment and avoiding unnecessary treatment interruptions.

NRTI based HIV treatment therefore represents an important part of modern antiretroviral therapy, but medication selection is individualized. Factors such as the person's treatment history, laboratory findings, hepatitis B status, kidney function, other medicines, and potential resistance can all influence the appropriate regimen. Treatment decisions should be made with a qualified healthcare professional using current HIV treatment guidelines and the individual's clinical information.